Subscribe
Subscribe for the Newsletter
Mobile Navigation
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Experience
Market Research
Directory
Close
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
CDMO
Sort By
Newest First
Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.
Explore
About Us
Nice Insight
That's Nice
Reach Our Team
Contact Us
Advertise
LinkedIn
My Account
Login
Sign up
Subscribe for the newsletter
© 2026 PHARMA'S ALMANAC. All rights reserved.
Privacy Policy
Terms And Conditions
(914)
1 / 46
Liquids & Semisolids
What Makes a Great Liquid Oral Dose CDMO?
Rob Terry
TriRx Pharmaceutical Services
PAO-07-26-CL-01
Jul 22, 2026
LAI Formulation
The Formulation Science Behind Extended Drug Release
Pharma's Almanac
PAO-07-26-PA-03
Jul 9, 2026
Organoids
Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research
Seahee Kim, Ph.D.
Samsung Biologics
PAO-06-26-CL-04
Jul 1, 2026
Bioavailability
AustinPx Expands KinetiSol™ Technology Commercial Access through Thermo Fisher Scientific Collaboration
AustinPx
PR-06-26-03
Jun 30, 2026
Outsourcing
Do you expect continued movement away from one-stop-shop outsourcing toward deeper modality-specific expertise?
Pharma's Almanac
PAO-06-26-RT-01
Jun 29, 2026
Tech Transfer
Why Successful Scale-Up and Transfer Capabilities Increasingly Determine Outsourcing Success
Pharma's Almanac
PAO-06-26-PA-22
Jun 25, 2026
LNP Strategy
Building Better RNA Medicines Through Smarter LNP Formulation Strategy
Aula Al Muslim, Ph.D.
Recipharm Advanced Bio
PAO-06-26-CL-03
Jun 22, 2026
U.S. CDMO Capacity
More Than Capacity: What the Latest U.S. CDMO Expansion Wave Reveals About Specialized Manufacturing Demand
Pharma's Almanac
PAO-06-26-PA-18
Jun 22, 2026
Supply Chain
Outsourcing, Fragmentation, and the New Supply Chain Resilience Challenge
Pharma's Almanac
PAO-06-26-PA-07
Jun 12, 2026
Outsourcing
The Hidden Operational Costs of Multi-Vendor Outsourcing Models
Pharma's Almanac
PAO-06-26-PA-06
Jun 11, 2026
Peptides
Enabling the Commercialization of Peptide Therapeutics with Manufacturing Advances
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-06-26-PA-13
Jun 9, 2026
Roundtable
How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?
Pharma's Almanac
PAO-05-26-RT-02
May 27, 2026
Psychedelics CMC
The CMC Challenge for Psychedelic Drugs
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-21
May 22, 2026
Peptide Production
Peptide Manufacturing Enters the Industrial Era
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-17
May 18, 2026
Vaccine Development
Proving a Robust and Accelerated Human Vaccine Platform Provided the Foundation for a Uniquely Capable Biologics CDMO
Laura Ferrer, Ph.D.
HIPRA Biotech Services
PAO-03-26-CL-03
Apr 14, 2026
Outsourcing Regs
Navigating Global Regulatory Expectations in Outsourced Manufacturing
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-26-PA-07
Apr 10, 2026
Formulation
Quotient Sciences and Intrepid Labs form Strategic Partnership to Accelerate AI-guided Formulation Development
Quotient Sciences
PR-04-26-05
Apr 1, 2026
Clinical Partnership
Quotient Sciences and Biorasi Partner to Accelerate Early Phase Clinical Trials to Patient Proof-of-Concept
Quotient Sciences
PR-04-26-04
Apr 1, 2026
Drug Development
Lindus Health and Quotient Sciences Partner to Accelerate Drug Development from First-in-Human to Pivotal Trials
Quotient Sciences
PR-04-26-03
Apr 1, 2026
Rare Disease
Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment
Quotient Sciences
PR-04-26-02
Apr 1, 2026
1 / 46